{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:12:52Z","timestamp":1788469972069,"version":"build-2803163510"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer, and early detection is associated with better survival. Mesothelin, fibulin-3 and osteopontin have been suggested as screening biomarkers. The study conducted a meta-analysis of the mean differences of mesothelin, osteopontin and fibulin-3 in blood and pleural samples. PubMed searches were conducted for studies that measured levels of mesothelin, osteopontin and fibulin-3 in participants with MPM compared with malignancy, benign lung disease or healthy participants. Thirty-two studies with mesothelin levels, 12 studies with osteopontin levels and 9 studies with fibulin-3 levels were included in the meta-analysis. Statistically significant mean differences were seen between MPM patients and all other comparison groups for mesothelin blood and pleural levels. Statistically significant differences in blood osteopontin levels were seen between participants with benign lung disease and healthy participants compared with participants with MPM, but not when comparing participants with cancer with MPM participants. There were not enough studies that reported osteopontin levels in pleural fluid to complete a meta-analysis. Statistically significant differences were seen in both blood and pleural levels of fibulin-3 in MPM patients compared with all other groups. On the basis of these results, mesothelin and fibulin-3 levels appear to be significantly lower in all control groups compared with those with MPM, making them good candidates for screening biomarkers. Osteopontin may be a useful biomarker for screening healthy individuals or those with benign lung disease but would not be useful for screening patients with malignancies.<\/jats:p>","DOI":"10.1093\/carcin\/bgz103","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T15:12:00Z","timestamp":1559661120000},"page":"1320-1331","source":"Crossref","is-referenced-by-count":21,"title":["Biomarkers for malignant pleural mesothelioma: a meta-analysis"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1318-8316","authenticated-orcid":false,"given":"Christina N","family":"Gillezeau","sequence":"first","affiliation":[{"name":"Institute for Translational Epidemiology and Department of Population Health Science and Policy, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"van Gerwen","sequence":"additional","affiliation":[{"name":"Institute for Translational Epidemiology and Department of Population Health Science and Policy, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ramos","sequence":"additional","affiliation":[{"name":"Institute for Translational Epidemiology and Department of Population Health Science and Policy, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bian","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute for Translational Epidemiology and Department of Population Health Science and Policy, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Flores","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Taioli","sequence":"additional","affiliation":[{"name":"Institute for Translational Epidemiology and Department of Population Health Science and Policy, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"2019112506303266500_CIT0001","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J. Thorac. Oncol.,"},{"key":"2019112506303266500_CIT0002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"2019112506303266500_CIT0003","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J Clin Oncol,"},{"key":"2019112506303266500_CIT0004","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U SA,"},{"key":"2019112506303266500_CIT0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijsu.2017.10.034","article-title":"The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database","volume":"48","author":"Wang","year":"2017","journal-title":"Int. J. Surg.,"},{"key":"2019112506303266500_CIT0006","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jtho.2017.04.002","article-title":"Epidemiology of environmental exposure and malignant mesothelioma","volume":"12","author":"Liu","year":"2017","journal-title":"J. Thorac. Oncol.,"},{"key":"2019112506303266500_CIT0007","article-title":"Biomarkers for early diagnosis and prognosis of malignant pleural mesothelioma: the quest goes on","volume":"10: E203","author":"Ledda","year":"2018","journal-title":"Cancers (Basel)."},{"key":"2019112506303266500_CIT0008","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet,"},{"key":"2019112506303266500_CIT0009","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: a systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br. J. Cancer,"},{"key":"2019112506303266500_CIT0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0004563217741145","article-title":"Biomarkers in mesothelioma","volume":"55","author":"Arnold","year":"2018","journal-title":"Ann. Clin. Biochem.,"},{"key":"2019112506303266500_CIT0091","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J. Clin. Oncol.,"},{"key":"2019112506303266500_CIT0010","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med.,"},{"key":"2019112506303266500_CIT0011","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.18632\/oncotarget.14712","article-title":"Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis","volume":"8","author":"Pei","year":"2017","journal-title":"Oncotarget,"},{"key":"2019112506303266500_CIT0012","doi-asserted-by":"crossref","first-page":"84851","DOI":"10.18632\/oncotarget.12707","article-title":"Diagnostic value of fibulin-3 for malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget,"},{"key":"2019112506303266500_CIT0013","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum mesothelin and other biomarkers: what have we learned in the last decade?","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J. Thorac. Dis.,"},{"key":"2019112506303266500_CIT0014","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.21037\/jtd.2017.12.17","article-title":"Biomarkers in the prevention and follow-up of workers exposed to asbestos","volume":"10","author":"Foddis","year":"2018","journal-title":"J. Thorac. Dis.,"},{"key":"2019112506303266500_CIT0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic and prognostic biomarkers for malignant mesothelioma: an update","volume":"6","author":"Chen","year":"2017","journal-title":"Transl. Lung Cancer Res.,"},{"key":"2019112506303266500_CIT0016","doi-asserted-by":"crossref","first-page":"244","DOI":"10.21037\/atm.2017.06.60","article-title":"Diagnosis and prognosis-review of biomarkers for mesothelioma","volume":"5","author":"Sun","year":"2017","journal-title":"Ann. Transl. Med.,"},{"key":"2019112506303266500_CIT0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/fon.15.317","article-title":"Biomarkers and prognostic factors for malignant pleural mesothelioma","volume":"11","author":"Vigneri","year":"2015","journal-title":"Future Oncol.,"},{"key":"2019112506303266500_CIT0018","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MCP.0000000000000167","article-title":"Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma","volume":"21","author":"Creaney","year":"2015","journal-title":"Curr. Opin. Pulm. Med.,"},{"key":"2019112506303266500_CIT0019","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","article-title":"The established and future biomarkers of malignant pleural mesothelioma","volume":"41","author":"Panou","year":"2015","journal-title":"Cancer Treat. Rev.,"},{"key":"2019112506303266500_CIT0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann. Transl. Med.,"},{"key":"2019112506303266500_CIT0021","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/17530059.2013.786038","article-title":"Current and future options for the diagnosis of malignant pleural effusion","volume":"7","author":"Rodriguez-Panadero","year":"2013","journal-title":"Expert Opin. Med. Diagn.,"},{"key":"2019112506303266500_CIT0022","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus Report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J Thorac Oncol,"},{"key":"2019112506303266500_CIT0023","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cca.2014.02.024","article-title":"Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"433","author":"Hu","year":"2014","journal-title":"Clin. Chim. Acta.,"},{"key":"2019112506303266500_CIT0024","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-12-394384-2.00006-1","article-title":"Asbestos-related disease: screening and diagnosis","volume":"57","author":"Rodr\u00edguez Portal","year":"2012","journal-title":"Adv. Clin. Chem.,"},{"key":"2019112506303266500_CIT0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1183\/09031936.00064413","article-title":"Mesothelin and osteopontin","volume":"42","author":"Pantazopoulos","year":"2013","journal-title":"Eur. Respir. J.,"},{"key":"2019112506303266500_CIT0026","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J. Thorac. Oncol.,"},{"key":"2019112506303266500_CIT0027","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0031-1272874","article-title":"Update on malignant pleural mesothelioma","volume":"32","author":"Campbell","year":"2011","journal-title":"Semin. Respir. Crit. Care Med.,"},{"key":"2019112506303266500_CIT0028","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-642-10862-4_10","article-title":"Early stages of mesothelioma, screening and biomarkers","volume":"189","author":"Klebe","year":"2011","journal-title":"Recent Results Cancer Res.,"},{"key":"2019112506303266500_CIT0029","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.semtcvs.2009.06.007","article-title":"Current status of screening for malignant pleural mesothelioma","volume":"21","author":"Pass","year":"2009","journal-title":"Semin. Thorac. Cardiovasc. Surg.,"},{"key":"2019112506303266500_CIT0030","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1378\/chest.08-2665","article-title":"Malignant pleural mesothelioma: an update on biomarkers and treatment","volume":"136","author":"Ray","year":"2009","journal-title":"Chest,"},{"key":"2019112506303266500_CIT0031","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/MCP.0b013e32832b98eb","article-title":"Serum and pleural fluid biomarkers for mesothelioma","volume":"15","author":"Creaney","year":"2009","journal-title":"Curr. Opin. Pulm. Med.,"},{"key":"2019112506303266500_CIT0032","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MCP.0b013e328302851d","article-title":"Malignant mesothelioma 2008","volume":"14","author":"Zervos","year":"2008","journal-title":"Curr. Opin. Pulm. Med.,"},{"key":"2019112506303266500_CIT0033","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2007.07.012","article-title":"Assessment of tumor response in malignant pleural mesothelioma","volume":"33","author":"Ceresoli","year":"2007","journal-title":"Cancer Treat. Rev.,"},{"key":"2019112506303266500_CIT0034","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCP.0b013e32812144bb","article-title":"Biomarkers for mesothelioma","volume":"13","author":"Scherpereel","year":"2007","journal-title":"Curr. Opin. Pulm. Med.,"},{"key":"2019112506303266500_CIT0035","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/jcb.20828","article-title":"Cellular and molecular parameters of mesothelioma","volume":"98","author":"Ramos-Nino","year":"2006","journal-title":"J. Cell. Biochem.,"},{"key":"2019112506303266500_CIT0036","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.21037\/jtd.2017.10.88","article-title":"Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review","volume":"10","author":"Bruno","year":"2018","journal-title":"J. Thorac. Dis.,"},{"key":"2019112506303266500_CIT0037","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest,"},{"key":"2019112506303266500_CIT0038","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/172460081002500307","article-title":"Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma","volume":"25","author":"Cristaudo","year":"2010","journal-title":"Int. J. Biol. Markers,"},{"key":"2019112506303266500_CIT0039","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/JTO.0b013e31824c9272","article-title":"CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions","volume":"7","author":"Blanquart","year":"2012","journal-title":"J. Thorac. Oncol.,"},{"key":"2019112506303266500_CIT0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/annhyg\/mew038","article-title":"Mesothelioma among motor vehicle mechanics: an updated review and meta-analysis","volume":"60","author":"Garabrant","year":"2016","journal-title":"Ann. Occup. Hyg.,"},{"key":"2019112506303266500_CIT0041","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol.,"},{"key":"2019112506303266500_CIT0042","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med.,"},{"key":"2019112506303266500_CIT0043","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bmj.39343.408449.80","article-title":"Uncertainty in heterogeneity estimates in meta-analyses","volume":"335","author":"Ioannidis","year":"2007","journal-title":"BMJ,"},{"key":"2019112506303266500_CIT0044","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/01243894-200602000-00013","article-title":"Soluble mesothelin related protein in mesothelioma","volume":"1","author":"Creaney","year":"2006","journal-title":"J. Thorac. Oncol.,"},{"key":"2019112506303266500_CIT0045","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/JTO.0b013e318180477b","article-title":"Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma","volume":"3","author":"Creaney","year":"2008","journal-title":"J. Thorac. Oncol.,"},{"key":"2019112506303266500_CIT0046","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","article-title":"Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma","volume":"82","author":"Creaney","year":"2013","journal-title":"Lung Cancer,"},{"key":"2019112506303266500_CIT0047","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/874212","article-title":"Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum","volume":"35","author":"Creaney","year":"2013","journal-title":"Dis. Markers,"},{"key":"2019112506303266500_CIT0048","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider","year":"2008","journal-title":"J. Thorac. Oncol.,"},{"key":"2019112506303266500_CIT0049","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1515\/CCLM.2010.066","article-title":"Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels","volume":"48","author":"Rai","year":"2010","journal-title":"Clin. Chem. Lab. Med.,"},{"key":"2019112506303266500_CIT0050","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e31828f696b","article-title":"Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer","volume":"8","author":"Muley","year":"2013","journal-title":"J. Thorac. Oncol.,"},{"key":"2019112506303266500_CIT0051","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2008.02.012","article-title":"Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin","volume":"62","author":"Iwahori","year":"2008","journal-title":"Lung Cancer,"},{"key":"2019112506303266500_CIT0052","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1373\/clinchem.2008.121913","article-title":"Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum","volume":"55","author":"Hollevoet","year":"2009","journal-title":"Clin. Chem.,"},{"key":"2019112506303266500_CIT0053","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00204-010-0580-2","article-title":"Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos","volume":"85","author":"Gube","year":"2011","journal-title":"Arch. Toxicol.,"},{"key":"2019112506303266500_CIT0054","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5301\/JBM.2011.8614","article-title":"Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide","volume":"26","author":"Dipalma","year":"2011","journal-title":"Int. J. Biol. Markers,"},{"key":"2019112506303266500_CIT0055","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin. Cancer Res.,"},{"key":"2019112506303266500_CIT0056","first-page":"5517","article-title":"YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis","volume":"33","author":"Corradi","year":"2013","journal-title":"Anticancer Res.,"},{"key":"2019112506303266500_CIT0057","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12885-017-3209-5","article-title":"Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin","volume":"17","author":"Ak","year":"2017","journal-title":"BMC Cancer,"},{"key":"2019112506303266500_CIT0058","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1055-9965.EPI-08-0422","article-title":"Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure","volume":"18","author":"Rodr\u00edguez Portal","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev.,"},{"key":"2019112506303266500_CIT0059","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/epi.6.8.16074","article-title":"The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma","volume":"6","author":"Nelson","year":"2011","journal-title":"Epigenetics,"},{"key":"2019112506303266500_CIT0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1055-9965.EPI-07-0607","article-title":"Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study","volume":"17","author":"Amati","year":"2008","journal-title":"Cancer Epidemiol. Biomarkers Prev.,"},{"key":"2019112506303266500_CIT0061","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejcdt.2012.10.016","article-title":"Combined blood and pleural levels of mesothelin and osteopontin for the diagnosis of malignant pleural mesothelioma","volume":"61","author":"Ashour","year":"2012","journal-title":"Egypt. J. Chest Dis. Tuberc.,"},{"key":"2019112506303266500_CIT0062","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3892\/etm_00000048","article-title":"Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma","volume":"1","author":"Fujimoto","year":"2010","journal-title":"Exp. Ther. Med.,"},{"key":"2019112506303266500_CIT0063","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.21873\/anticanres.11460","article-title":"Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma","volume":"37","author":"Battolla","year":"2017","journal-title":"Anticancer Res.,"},{"key":"2019112506303266500_CIT0064","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/07357907.2012.749265","article-title":"Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology","volume":"31","author":"Canessa","year":"2013","journal-title":"Cancer Invest.,"},{"key":"2019112506303266500_CIT0065","doi-asserted-by":"crossref","first-page":"413946","DOI":"10.1155\/2014\/413946","article-title":"Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma","volume":"2014","author":"Creaney","year":"2014","journal-title":"Dis. Markers,"},{"key":"2019112506303266500_CIT0066","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1164\/rccm.200811-1729OC","article-title":"Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions","volume":"180","author":"Davies","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med.,"},{"key":"2019112506303266500_CIT0067","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1515\/CCLM.2011.242","article-title":"Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma","volume":"49","author":"Yamada","year":"2011","journal-title":"Clin. Chem. Lab. Med.,"},{"key":"2019112506303266500_CIT0068","doi-asserted-by":"crossref","first-page":"e0185850","DOI":"10.1371\/journal.pone.0185850","article-title":"Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: a retrospective study in a single center","volume":"12","author":"Otoshi","year":"2017","journal-title":"PLoS One,"},{"key":"2019112506303266500_CIT0069","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"Creaney","year":"2007","journal-title":"Thorax,"},{"key":"2019112506303266500_CIT0070","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejcdt.2013.04.005","article-title":"Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis","volume":"62","author":"Amany","year":"2013","journal-title":"Egypt. J. Chest Dis. Tuberc.,"},{"key":"2019112506303266500_CIT0071","first-page":"2707","article-title":"Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma","volume":"33","author":"Ferro","year":"2013","journal-title":"Anticancer Res.,"},{"key":"2019112506303266500_CIT0072","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin. Cancer Res.,"},{"key":"2019112506303266500_CIT0073","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1183\/09031936.00148211","article-title":"A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions","volume":"41","author":"Hooper","year":"2013","journal-title":"Eur. Respir. J.,"},{"key":"2019112506303266500_CIT0074","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann. Thorac. Surg.,"},{"key":"2019112506303266500_CIT0075","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med.,"},{"key":"2019112506303266500_CIT0076","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2011.02.007","article-title":"Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma\u2013which is best?","volume":"74","author":"Creaney","year":"2011","journal-title":"Lung Cancer,"},{"key":"2019112506303266500_CIT0077","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin. Cancer Res.,"},{"key":"2019112506303266500_CIT0078","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11604-010-0449-6","article-title":"Preliminary study of positron emission tomography\/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease","volume":"28","author":"Kurata","year":"2010","journal-title":"Jpn. J. Radiol.,"},{"key":"2019112506303266500_CIT0079","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N. Engl. J. Med.,"},{"key":"2019112506303266500_CIT0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/172460080902400208","article-title":"Osteopontin is not a specific marker in malignant pleural mesothelioma","volume":"24","author":"Paleari","year":"2009","journal-title":"Int. J. Biol. Markers,"},{"key":"2019112506303266500_CIT0081","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","article-title":"Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma","volume":"6","author":"Cristaudo","year":"2011","journal-title":"J. Thorac. Oncol.,"},{"key":"2019112506303266500_CIT0082","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00408-013-9526-9","article-title":"Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos","volume":"192","author":"Bayram","year":"2014","journal-title":"Lung,"},{"key":"2019112506303266500_CIT0083","doi-asserted-by":"crossref","first-page":"1725354","DOI":"10.1155\/2017\/1725354","article-title":"Plasma fibulin-3 as a potential biomarker for patients with asbestos-related diseases in the Han population","volume":"2017","author":"Jiang","year":"2017","journal-title":"Dis. Markers,"},{"key":"2019112506303266500_CIT0084","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of new biomarkers in the prediction of Malignant Mesothelioma in subjects with environmental asbestos exposure","volume":"194","author":"Demir","year":"2016","journal-title":"Lung,"},{"key":"2019112506303266500_CIT0085","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br. J. Cancer,"},{"key":"2019112506303266500_CIT0086","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax,"},{"key":"2019112506303266500_CIT0087","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejcdt.2013.10.004","article-title":"Role of fibulin-3 in the diagnosis of malignant mesothelioma","volume":"63","author":"Agha","year":"2014","journal-title":"Egypt. J. Chest Dis. Tuberc.,"},{"key":"2019112506303266500_CIT0088","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ejcdt.2014.08.001","article-title":"Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions","volume":"63","author":"Elgazzar","year":"2014","journal-title":"Egypt. J. Chest Dis. Tuberc.,"}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/advance-article-pdf\/doi\/10.1093\/carcin\/bgz103\/28882177\/bgz103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/40\/11\/1320\/31112547\/bgz103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/40\/11\/1320\/31112547\/bgz103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T06:31:24Z","timestamp":1574663484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/40\/11\/1320\/5512004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":90,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,6,5]]},"published-print":{"date-parts":[[2019,11,25]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgz103","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,6,5]]}}}